Sanofi - Contingent Value Rig (GCVRZ)

[Letgoofmyfannie]

Two Posts on GCVRZ from YM Board:

[both seem worth knowing about, I haven't verified these as of yet]


OFF LABEL USE MARKETING
by ghin10 • 8 hours ago

The Federal District Court for the Southern District of New York ruled that FDA could not enforce its off-label marketing ban against Amarin Pharma Inc.'s fish oil drug, Vascepa, as long as the drug company gave doctors and others truthful accounts of medical studies of the drug's off label uses. See Saturday/Sunday (8/8, 8/9/2015 ) edition of WSJ, B1. Will be interesting to see if Genzyme uses this to promote Lemtrada for off label purposes with appropriate and full disclosure. Not saying it is a game changer, but could be an important marketing boost for US sales.




northforkinvestor • Aug 17, 2015 4:07 PM

not necessarily: on or after 4/1/17 SNY can optionally purchase and cancel all outstanding CVRs at the average trading price of the CVRs if the VWOP CVR trading price is less than $.50 and Lemtrada sales in the prior 4 qtr period were less than $1 bb in the aggregate.